MK 8521

Drug Profile

MK 8521

Alternative Names: MK-8521

Latest Information Update: 10 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Merck & Co
  • Class Antihyperglycaemics
  • Mechanism of Action Glucagon like peptide 1 receptor agonists; Glucagon receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Type 2 diabetes mellitus

Most Recent Events

  • 11 Apr 2017 Merck Sharp & Dohme completes a phase-II trial in Type-2 diabetes mellitus in USA, Australia, Colombia, Guatemala, Israel, New Zealand, Spain (SC) (NCT02492763) (EudraCT2016-002056-25)
  • 16 Jul 2016 No recent reports of development identified for phase-I development in Type-2-diabetes-mellitus(In volunteers) in Belgium (SC, Injection)
  • 13 Jul 2015 Merck plans a phase II trial for Type 2 diabetes mellitus in USA (NCT02492763)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top